Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.
Merck's antiviral business suffered some serious blows this year, but it now boasts a new product: Prevymis, a CMV fighter approved by the FDA on Thursday.
Despite blasting pharma for "getting away with murder," President Donald Trump is close to naming a former Eli Lilly executive as HHS secretary.
Five more lawmakers are piling on Allergan for the company's controversial tribal licensing deal.
Score a win for pharma in the state-by-state war over drug costs: Ohioans have refused a measure that would have set pricing limits.
Roche's Alecensa nabbed a new FDA approval to treat first-line lung cancer, putting it on even footing with Pfizer's Xalkori and Novartis'…
Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.
Valeant has overcome manufacturing problems at a Bausch & Lomb plant to win approval of its long-delayed eye drug.
Congress hasn't made progress on pricing reform, but a group of lawmakers are pushing to reduce waste in pharmaceuticals.
AbbVie and J&J got a scare this Halloween when the FDA approved AstraZeneca’s Imbruvica rival Calquence.